Documents | Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

Review Decision - January 2010 information
Appendix A: Decision paper considered by the Institute's Guidance Executive ^{PDF 88.64 KB} 27 January 2010
Review Proposal - August 2009 information
Appendix A: provisional matrix of stakeholders ^{PDF 33.94 KB} 07 September 2009
Appendix B: proposal paper presented to the Institute's Guidance Executive ^{PDF 79.37 KB} 07 September 2009

Colorectal cancer (metastatic) - bevacizumab & cetuximab: appeal

Colorectal cancer (metastatic) - bevacizumab & cetuximab: appeal information
Appeal announcement: Bevacizumab and cetuximab for metastatic colorectal cancer information
Appeal received from Merck Pharmaceuticals
Initial scrutiny letter ^{PDF 103.08 KB} 27 November 2006
Merck Pharmaceuticals response to the scrutiny letter ^{PDF 127.11 KB} 27 November 2006
Appeals received
Merck Pharmaceuticals 1 ^{PDF 47.94 KB} 27 November 2006
Merck Pharmaceuticals 2 ^{PDF 938.2 KB} 27 November 2006
Appeal received from Bowel Cancer UK and Cancerbackup (joint appeal)
Appeals received ^{PDF 41.4 KB} 27 November 2006
Initial scrutiny letter ^{PDF 96.24 KB} 27 November 2006
Bowel Cancer UK & Cancerbackup's response to the scrutiny letter ^{PDF 71.5 KB} 27 November 2006
Final Scrutiny letter ^{PDF 43.37 KB} 27 November 2006
Colorectal cancer (metastatic) - bevacizumab & cetuximab: Appeal panel decision ^{PDF 42.67 KB} 24 January 2007

Colorectal cancer (metastatic) - bevacizumab & cetuximab - Final appraisal determination

Colorectal cancer (metastatic) - bevacizumab & cetuximab - Final appraisal determination information
Final appraisal determination ^{PDF 173.79 KB} 21 August 2006
Response to consultee and commentator comments and response to public and web comments on the ACD ^{PDF 243.68 KB} 21 August 2006
Consultee and commentator comments on the ACD
Royal College of Physicians ^{PDF 46.2 KB} 21 August 2006
Royal College of Pathologists ^{PDF 70.68 KB} 21 August 2006
Royal College of Nursing ^{PDF 27.93 KB} 21 August 2006
Roche Products Ltd ^{PDF 129.43 KB} 21 August 2006
NHS Quality Improvement Scotland ^{PDF 28.42 KB} 21 August 2006
Merck Pharmaceuticals ^{PDF 162.89 KB} 21 August 2006
Cancer Backup ^{PDF 21.58 KB} 21 August 2006
Bowel Cancer UK ^{PDF 23.17 KB} 21 August 2006
Anthoney ^{PDF 21.3 KB} 21 August 2006

Colorectal cancer (advanced) - bevacizumab & cetuximab (appraisal consultation document)

Colorectal cancer (advanced) - bevacizumab & cetuximab (appraisal consultation document) information

Overview

Overview ^{PDF 139.55 KB} 02 June 2006

Colorectal cancer (metastatic) - bevacizumab & cetuximab: Assessment report

Colorectal cancer (metastatic) - bevacizumab & cetuximab: Assessment report ^{PDF 1.11 MB} 02 June 2006

Consultee and commentator comments on the assessment report

Consultee and commentator comments on the assessment report
Bowel Cancer UK ^{PDF 71.71 KB} 02 June 2006
Merck Pharmaceuticals ^{PDF 582.09 KB} 02 June 2006
NHS Quality Improvement Scotland ^{PDF 30.51 KB} 02 June 2006
Roche ^{PDF 319.85 KB} 02 June 2006
Royal College of Nursing ^{PDF 107.94 KB} 02 June 2006
Royal College of Pathologists ^{PDF 71.63 KB} 02 June 2006

Non-manufacturer submissions

Non-manufacturer submissions
Association of Coloproctologists of Great Britain ^{PDF 326.12 KB} 02 June 2006
Beating Bowel Cancer ^{PDF 510.93 KB} 02 June 2006
Bowel Cancer UK (formerly known as Colon Cancer Concern) ^{PDF 2.02 MB} 02 June 2006
Cancerbackup ^{PDF 252.23 KB} 02 June 2006
Royal College of Nursing ^{PDF 192.97 KB} 02 June 2006
Royal College of Pathologists ^{PDF 46.28 KB} 02 June 2006
Royal College of Physicians (support letter) ^{PDF 40.76 KB} 02 June 2006

Assessment groups response to comments on the assessment report

ScHARR ^{PDF 348.67 KB} 02 June 2006

Manufacturer submissions

Manufacturer submissions
Roche ^{PDF 270.77 KB} 02 June 2006
Merck ^{PDF 190.8 KB} 02 June 2006

Expert written personal statements

Expert written personal statements
Anthoney ^{PDF 348.39 KB} 02 June 2006
Rhys Evans ^{PDF 217.45 KB} 02 June 2006
Smith ^{PDF 214.56 KB} 02 June 2006

Final protocol

Final protocol ^{PDF 207.53 KB} 28 June 2005

Summary of comments on the draft scope

Summary of comments on the draft scope ^{PDF 46.59 KB} 06 May 2005

Final scope

Final scope ^{PDF 26.43 KB} 06 May 2005

Archive: Draft scope

Archive: Draft scope ^{PDF 26.24 KB} 06 May 2005

Summary of comments on the provisional matrix of consultees and commentators

Summary of comments on the provisional matrix of consultees and commentators ^{PDF 20.04 KB} 06 May 2005

Archive: Provisional matrix of consultees and commentators

Archive: Provisional matrix of consultees and commentators ^{PDF 28.79 KB} 06 May 2005

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder

2004/027 NICE asked to develop guidance on the care of drug misuse, medicines for prostate cancer, and management of attention deficit hyperactivity disorder information